Of these, combined anti-vascular endothelial growth factor (anti-VEGF) and immunotherapies are expected to resolve the issues associated with the immunosuppressive tumor microenvironment of HCC (Fukumura et al., 2018). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.